NewsBenzingaJupiter Neurosciences Doses First Participant In Its Phase 2a RESET Clinical Study Of JOTROL To Treat Parkinson's Disease Jupiter Neurosciences Doses First Participant In Its Phase 2a RESET Clinical Study Of JOTROL To Treat Parkinson's Disease Benzinga 2026.10.06 15:18 (GMT+0) Open on Benzinga Other news Morgan Stanley Maintains Overweight on Walt Disney, Raises Price Target to $138 What's Going On With Dell Technologies Stock Thursday? This Lowe’s Analyst Cites 7 Takeaways From Earnings Call Morgan Stanley Maintains Overweight on Target, Raises Price Target to $185 Plug Power CFO Reiterates Q4 2026 Positive EBITDAS Target Morgan Stanley Maintains Overweight on McGraw Hill, Raises Price Target to $15